Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Selodenoson
- Development stage
- Phase 2
- Lead developer
- UCB
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Selodenoson is a small molecule drug that functions as a selective agonist of the adenosine A1 receptor (A1AR). It is being developed to slow heart rate in patients with atrial fibrillation and to treat other arrhythmias. Its mechanism involves targeting the A1 receptor to produce negative dromotropic effects, which can rapidly reduce heart rate.
- Other names
- selodenosonumGR 56072GR56072GR-56072RG 14202RG14202RG-14202DTI 0009DTI0009DTI-0009DT-009DT009DT 009
02
Targets
ADORA1 (Adenosine receptor A1 subtype)
Beyond the preview
Go deeper on Selodenoson.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Selodenoson.